Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The impact of reduced PLCG2 expression on microglial biology and disease pathology in a murine model of Alzheimer’s disease

ABSTRACT: The impact of reduced PLCG2 expression on microglial biology and disease pathology in a murine model of Alzheimer’s disease

PROVIDER: PRJNA805219 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

The impact of reduced PLCG2 expression on microglial biology and disease pathology in a murine model of Alzheimer’s disease

Project description:Differential expression analysis identified inflammation-related pathways in AD samples with reduced PLCG2 expression

2025-01-01 | GSE196502 | GEO

Alzheimer's disease-associated PLCG2 variants alter microglial state and function in human iPSC-derived microglia-like cells

Project description:BACKGROUND: Variants of PLCG2, a key microglial immune signaling protein, are genetically linked to Alzheimer’s disease (AD) risk. Understanding how PLCG2 variants alter microglial function is critical for identifying mechanisms that drive neurodegeneration or resiliency in AD. METHODS: iPSC-derived microglia carrying the protective PLCG2P522R or risk-conferring PLCG2M28L variants, or loss of PLCG2, were generated to ascertain the impact on microglial transcriptome and function. RESULTS: Protective PLCG2P522R microglia showed significant transcriptomic similarity to isogenic controls. In contrast, risk-conferring PLCG2M28L microglia shared similarities with PLCG2KO microglia, with functionally reduced TREM2 expression, blunted inflammatory responses, and increased proliferation and cell death. Uniquely, PLCG2P522R microglia showed elevated cytokine secretion after LPS stimulation and were protected from apoptosis. DISCUSSION: These findings demonstrate that PLCG2 variants drive distinct microglia transcriptomes that influence microglial functional responses that could contribute to AD risk and protection. Targeting PLCG2-mediated signaling may represent a powerful therapeutic strategy to modulate neuroinflammation.

2025-10-09 | GSE308813 | GEO

PLCG2 modulates TREM2 expression and signaling in response to Alzheimer’s disease pathology 

Project description:Phospholipase C gamma 2 (PLCG2) is an intracellular effector of microglial cell surface receptors, including TREM2. Variants which alter PLCG2 activity impact Alzheimer’s disease (AD) risk, but the effects of PLCG2 deficiency in AD remain unclear.

2025-05-14 | GSE291648 | GEO

Genetic Variants of Phospholipase C-γ2 Confer Altered Microglial Phenotypes and Differential Risk for Alzheimer’s Disease [snRNA-seq]

Project description:The PLCG2 variants bidirectionally modulate disease pathology by inducing distinct transcriptional programs that identify microglial subpopulations associated with protective or detrimental phenotypes

2023-09-14 | GSE237494 | GEO

Genetic Variants of Phospholipase C-γ2 Confer Altered Microglial Phenotypes and Differential Risk for Alzheimer’s Disease [bulk RNA-seq]

2023-09-14 | GSE237493 | GEO

Non-microglial downregulation of PLCG2 impairs synaptic function and elicits Alzheimer disease-related hallmarks

Project description:Non-microglial downregulation of PLCG2 impairs synaptic function and elicits Alzheimer disease-related hallmarks

| PRJEB112198 | ENA

PLCG2 is Associated with the Inflammatory Response and is Induced by Amyloid Plaques in Alzheimer's Disease

Project description:Differential expression analysis in Plcg2-inactivated mouse model identified inflammation-related genes and pathways.

2022-02-07 | GSE195650 | GEO

PLCG2 modulates TREM2 expression and signaling in response to Alzheimer’s disease pathology 

Project description:PLCG2 modulates TREM2 expression and signaling in response to Alzheimer’s disease pathology 

| PRJNA1234569 | ENA

The VCAM1–ApoE pathway directs microglial chemotaxis and alleviates Alzheimer’s disease pathology

Project description:In Alzheimer’s disease (AD), sensome receptor dysfunction impairs microglial danger-associated molecular pattern (DAMP) clearance and exacerbates disease pathology. While extrinsic signals including interleukin-33 (IL-33) can restore microglial DAMP clearance, it remains largely unclear how the sensome receptor(s) is regulated and interacts with DAMP during phagocytic clearance. Here, we show that IL-33 induces VCAM1 in microglia, which promotes microglial chemotaxis toward amyloid-beta (Aβ) plaque-associated ApoE, and leads to Aβ clearance. We show that IL-33 stimulates a chemotactic state in microglia, characterized by Aβ-directed migration. Functional screening identified that VCAM1 directs microglial Aβ chemotaxis by sensing Aβ plaque-associated ApoE. Moreover, we found that disrupting VCAM1–ApoE interaction abolishes microglial Aβ chemotaxis, resulting in decreased microglial clearance of Aβ. In patients with AD, higher cerebrospinal fluid levels of soluble VCAM1 were correlated with impaired microglial Aβ chemotaxis. Together, our findings demonstrate that promoting VCAM1–ApoE-dependent microglial functions ameliorates AD pathology.

2023-07-18 | GSE208006 | GEO

Alzheimer's disease-associated PLCG2 variants alter microglial state and function in human iPSC-derived microglia-like cells

Project description:Alzheimer's disease-associated PLCG2 variants alter microglial state and function in human iPSC-derived microglia-like cells

| PRJNA1332737 | ENA